ANALYTE MONITORING SYSTEM AND METHOD

• US 20080071157A1
• Filed: 06/07/2007
• Published: 03/20/2008
• Est. Priority Date: 06/07/2006
• Status: Abandoned Application

• Current Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Peyser, Thomas, McGarraugh, Geoffrey, Mazza, John, Rebrin, Kerstin, Feldman, Benjamin, Goodnow, Timothy
• Application Number:
  US11/759,926
• Publication Number:
  US 20080071157A1
• Time in Patent Office: Days
• US Class Current: 600/347
• CPC Class Codes: A61B 2562/125 characterised by the manufacture of electrodes
• CPC Class Codes: A61B 5/076 Permanent implantations telemetry using implanted circuitry A61B5/0031; implanted stimulators for therapy A61N1/3605, A61N1/362, A61N1/372
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1486 using enzyme electrodes, e.g. with immobilised oxidase
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/1495 Calibrating or testing of in-vivo probes
• CPC Class Codes: A61B 5/7282 Event detection, e.g. detecting unique waveforms indicative of a medical condition A61B5/4094, A61B5/4818, A61B5/349, A61B5/0823 take precedence
• CPC Class Codes: A61B 5/746 Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms alarms per se G08B
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: C12Q 1/006 for glucose
• CPC Class Codes: G01N 33/48792 Data management, e.g. communication with processing unit for in vivo diagnostics A61B5/0002; transmission systems for measured values G08C

Abstract

Devices and methods for monitoring an analyte are provided. Embodiments include continuous analyte sensors having a high degree of accuracy.

Claims

1. A method of monitoring glucose levels, comprising:

determining glucose concentration using a first transcutaneously positioned analyte sensor; and

reporting glucose concentration to a user;

wherein a second sensor is not used to confirm the accuracy of the first transcutaneously positioned analyte sensor.

2. The method of claim 1, wherein determining comprises over a period of time ranging from about 1 day to about 7 days.

3. The method of claim 1, wherein the first transcutaneously positioned analyte sensor has at least about 85% of its paired data points within zone A of the Clarke Error Grid.

4. The method of claim 1, wherein the first transcutaneously positioned analyte sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.

5. The method of claim 1, wherein the first transcutaneously positioned analyte sensor has more than about 90% of its paired data points within zone A of the Clarke Error Grid.

6. The method of claim 1, wherein the first transcutaneously positioned analyte sensor is a glucose sensor.

7. The method of claim 1, comprising determining health related information based on the reported glucose concentration.

8. The method of claim 7 wherein the health related information includes a bolus amount.

9. The method of claim 7 wherein the health related information includes one or more of a food intake, medication dosage level, or activity level.

10. The method of claim 9, wherein the medication dosage level includes insulin dosage level.

11. The method of claim 1, comprising transmitting the reported glucose concentration.

12. The method of claim 11 wherein transmitting includes one or more of a wired transmission or a wireless transmission.

13. The method of claim 1 including calibrating the first transcutaneously positioned analyte sensor using single point calibration.

14. The method of claim 1 wherein the first transcutaneously positioned analyte sensor has at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.

15. The method of claim 14 wherein the first sensor has at least about 85% of its paired data points within zone A.

16. A method of monitoring glucose levels, comprising:

determining glucose concentration using a first transcutaneously positioned analyte sensor; and

reporting glucose concentration to a user;

wherein accuracy of the first transcutaneously positioned analyte sensor is established other than with a second sensor.

17. The method of claim 16, wherein the first transcutaneously positioned analyte sensor has at least about 85% of its paired data points within zone A of the Clarke Error Grid.

18. The method of claim 16, wherein the first transcutaneously positioned analyte sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.

19. The method of claim 16, wherein the first transcutaneously positioned analyte sensor has more than about 90% of its paired data points within zone A of the Clarke Error Grid.

20. The method of claim 16, wherein the first transcutaneously positioned analyte sensor is a glucose sensor.